Eli Lilly and Company (LLY)
| Market Cap | 929.76B |
| Revenue (ttm) | 59.42B |
| Net Income (ttm) | 18.41B |
| Shares Out | 895.38M |
| EPS (ttm) | 20.44 |
| PE Ratio | 50.80 |
| Forward PE | 32.91 |
| Dividend | $6.92 (0.67%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 3,852,823 |
| Open | 1,024.43 |
| Previous Close | 1,032.97 |
| Day's Range | 1,018.00 - 1,049.94 |
| 52-Week Range | 623.78 - 1,133.95 |
| Beta | 0.35 |
| Analysts | Strong Buy |
| Price Target | 1,104.11 (+6.33%) |
| Earnings Date | Feb 4, 2026 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $1,104.11, which is an increase of 6.33% from the latest price.
News
Eli Lilly, Nvidia team up in a $1B AI innovation lab.
Eli Lilly, Nvidia team up in a $1B AI innovation lab.
Our Top 10 High Growth Dividend Stocks - January 2026
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat...
Buy The Dip In LLY Stock?
Eli Lilly's recent decline of 3.76% following the FDA's delay regarding its oral weight-loss pill Orforglipron signifies a strategic buying chance rather than a matter of concern. Although the stock i...
Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Pharmaceutical companies are increasingly turning to artificial intelligence to accelerate R&D, betting on new modeling tools and automated labs to unlock efficiency gains across their pipeline.
MoneyShow's Best Investment Ideas For 2026: Part 4
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, an...
Eli Lilly and Company (LLY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Eli Lilly and Company (LLY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Eli Lilly CEO David Ricks on $1T market value, obesity pill launch and drug pipeline outlook
Eli Lilly chairman and CEO David Ricks joins 'Squawk on the Street' to discuss the path to becoming a trillion dollar company, launch of its obesity pill, new innovation at the company, drug pipeline ...
Expect a Busy Year in Obesity Drugs as New Pills Hit the Market
Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026's first half.
Nvidia to Invest $1 Billion in AI Drug Lab With Eli Lilly
Nvidia plans to invest $1 billion over five years in a new laboratory with Eli Lilly & Co., in an effort to speed up the use of AI in the pharmaceutical industry. Denny Fish, portfolio manager on the ...
Eli Lilly CFO on $1 billion Nvidia investment
NVIDIA plans to invest $1 billion over five years in a new laboratory with Eli Lilly and Company, aiming to speed up the use of artificial intelligence in the pharmaceutical industry. Heres what Eli L...
Eli Lilly CFO on $1 Billion AI Drug Lab Investment
Eli Lilly Chief Financial Officer Lucas Montarce says the company's weight-loss pill is on track to be approved in the US as early as the second quarter of this year. He speaks to Katie Greifeld at th...
Lilly says it's confident in weight-loss pill supply ahead of U.S. approval
Eli Lilly said on Monday it is confident about the supplies of its weight-loss pill orforglipron ahead of its anticipated U.S. approval in the coming months.
Nvidia Partners With Eli Lilly on AI Drug Laboratory
Nvidia plans to invest $1 billion over five years in a new laboratory with Eli Lilly & Co., aiming to speed up the use of artificial intelligence in the pharmaceutical industry. Jessica Nix has more o...
Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab
Nvidia and U.S. pharma giant Eli Lilly will spend $1 billion building a new joint research lab in the San Francisco Bay area over five years which will use Nvidia's newest generation Vera Rubin AI chi...
France has had no request for investment approval in biotech Abivax - official
France's finance ministry has received no request seeking investment approval in Abivax and has had no contact with Eli Lilly , a ministry official said on Monday, following media reports that the U.S...
Abivax stock rockets 30% on Eli Lilly takeover speculation
Abivax stock (EPA: ABVX) surged roughly 30% in early Paris trading Monday after French media reported that US pharmaceutical giant Eli Lilly was preparing a €15 billion ($17.5 billion) acquisition off...
Abivax Surges on Report Eli Lilly is Preparing $17.5 Billion Bid
Stock in the French company has been rising steadily since late July, and climbed as much as 30% in early trading Monday.
Abivax shares soar 23% as media report reignites M&A chatter
Shares in Abivax soared 23%, exceeding 121 euros, on Monday after a media report said U.S. pharma giant Eli Lilly was still interested in buying the French biotech company.
2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market
In 2026, new obesity pills will push the booming GLP-1 market into its next chapter. Pills may serve as a more convenient — and in certain cases cheaper — alternative to today's blockbuster injections...
Novo Nordisk and Eli Lilly can both gain GLP-1 market share this year, says Citi's Meacham
Geoff Meacham, Citi analyst, joins 'Fast Money' to talk what the year ahead holds for competition in the obesity drug market.
Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets
LOS ANGELES & BOSTON--(BUSINESS WIRE)--Vida Ventures (“Vida”), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a clinical-stage biotechnology company a...
Chai Discovery Announces Collaboration with Eli Lilly and Company to Accelerate Biologics Discovery
SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the AI company building a computer-aided design suite for molecules, announces Eli Lilly and Company collaboration.
Schrodinger to offer Eli Lilly's AI drug discovery platform on its software
Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, on its drug designing software.
A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year
Abivax stock rallied in 2025, far outpacing peers, as the French biotech surprised investors with a stellar data readout in July for its lead asset – an ulcerative colitis medicine. Now, analysts say ...